Skip to content

A study comparing the effectiveness and safety of Vortioxetine and Escitalopram in patients with depression.

Prospective, observational study on efficacy and safety of Vortioxetine in comparison to Escitalopram in patients with major depressive disorder - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111072
Enrollment
128
Registered
2026-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Dr MK Shah medical college and research institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with first episode major depressive disorder as per DSM 5 criteria, with MADRS score grater than or equal to 19. Patients who are prescribed vortioxetine or escitalopram by the treating psychiatrist. The patient, who is willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: Age less than 18 years or more than 60 years. Non consent for participation in the study. Patients who are not primarily diagnosed with major depressive disorder. Clinically significant endocrine, neurological or systemic illness (including hypo or hyperthyroidism, serious comorbid pulmonary, CNS, renal or hepatic disease, uncontrolled hypertension or diabetes). Patients with significant risk for suicide or MDD with psychotic features.

Design outcomes

Primary

MeasureTime frame
Change in HAM D, MADRS, CGI I, BC CCI score.Timepoint: Change in HAM D, MADRS, CGI I, BC CCI score at day 1, 14, 28 & 42

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Dhruti Merchant

Dr M.K Shah Medical college and research institute

dr.vk1987@gmail.com9228249767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026